If you'd like to get in touch, email me at mypinkgenes@gmail.com.

Make sure to subscribe to stay up to date with all my posts. And, don't forget to follow me on instagram and facebook. 

Take great care!

Kate

Subscribe Here

Breast Health/Prevention

Mammograms

Make this yours. Add images, text and links, or connect data from your collection.

Breast Density

Make this yours. Add images, text and links, or connect data from your collection.

Sports

Make this yours. Add images, text and links, or connect data from your collection.

Technology

Make this yours. Add images, text and links, or connect data from your collection.

"Adjuvant tamoxifen improved recurrence-free and overall survival for premenopausal patients with tumors showing >75% PR-positive nuclei. No effect could be shown in tumors with fewer PR-positive nuclei. The PR was a stronger predictor of treatment response than the ER. Based on these findings, we suggest the implementation of a fractioned rather than dichotomized immunohistochemical evaluation of hormone receptors in clinical practice, possibly with greater emphasis on the PR than the ER."

"Overall, the 5-year local recurrence rate after BCT was low, but varied by subtype as approximated using ER, PR, and HER-2 status. Local recurrence was particularly low for the luminal A subtype, but was less than 10% at 5 years for all subtypes. Although further follow-up is needed, these results may be useful in counseling patients about their anticipated outcome after BCT."

"When the 1–2 years tamoxifen ER-poor group was subcategorised according to PgR, those with PgR-poor status were seen to gain no benefit from tamoxifen but the PgR-positive and PgR-unknown groups had risk reductions for relapse with relative risks of 14% ± 12 and 15% ± 5, respectively, the latter was highly significant. The corresponding figures for 5 years tamoxifen were 8% ± 15 and 21% ± 15 respectively."

"Quantitative expression of ER and PgR and HER-2 status did not identify patients with differential relative benefit from anastrozole over tamoxifen: TTR was longer for anastrozole than for tamoxifen in all molecular subgroups. Low ER or PgR or high HER-2 expression are associated with a high risk of recurrence with either anastrozole or tamoxifen."

Add radiation guide here

Add chemo guide here

Add surgery guide here

IMG_1418
IMG_1769 2
IMG_1723
IMG_1700
IMG_1530
IMG_1512
IMG_1492
IMG_1804
IMG_1799
IMG_1442
IMG_1429
IMG_1791
IMG_1788
IMG_1348
IMG_1777
IMG_2169
IMG_2166
IMG_2139
IMG_2077
IMG_2074
IMG_3472
IMG_1839
IMG_3046
IMG_2075
IMG_1887
IMG_2473
P4260157
IMG_2295
IMG_2474
322508892
IMG_3223
P5200166
Show More